Johnson & Johnson

JNJ-N

NYSE:JNJ

139.99
0.51 (0.36%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia

Analysis and Opinions about JNJ-N

Signal
Opinion
Expert
BUY
BUY
October 23, 2002
Well rounded in different health areas.
Johnson & Johnson (JNJ-N)
October 23, 2002
Well rounded in different health areas.
Peter Brieger
Chairman & Chief Executive Officer, GlobeInvestment Capital Management
Price
$57.950
Owned
Unknown
BUY
BUY
October 15, 2002
Johnson & Johnson (JNJ-N)
October 15, 2002
Ray Steele
Vice President of Investments, Mavrix Fund Management
Price
$59.560
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
September 20, 2002
(Was a top pick on July 17. No change.) Still likes. A core holding.
Johnson & Johnson (JNJ-N)
September 20, 2002
(Was a top pick on July 17. No change.) Still likes. A core holding.
Paul O'Neil
Portfolio Manager, U.S. Equities, KBSH Capital Mngmnt
Price
$52.300
Owned
Unknown
DON'T BUY
DON'T BUY
August 16, 2002
Expensive now. Good long term hold.
Expensive now. Good long term hold.
Brad Willock
Vice President and Senior Portfolio Manager, RBC Asset Management
Price
$55.320
Owned
Unknown
TOP PICK
TOP PICK
July 17, 2002
Great price. Should appreciate 15% a year. Good numbers.
Great price. Should appreciate 15% a year. Good numbers.
Paul O'Neil
Portfolio Manager, U.S. Equities, KBSH Capital Mngmnt
Price
$51.240
Owned
Unknown
BUY
BUY
July 10, 2002
A good long term hold. Good price.
A good long term hold. Good price.
Peter Brieger
Chairman & Chief Executive Officer, GlobeInvestment Capital Management
Price
$50.300
Owned
Unknown
WAIT
WAIT
June 28, 2002
Benefiting from weaker US $. Wait for it to reverse its down trend.
Benefiting from weaker US $. Wait for it to reverse its down trend.
David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$52.260
Owned
Unknown
BUY
BUY
May 30, 2002
Bullish. International.No generic drug problems. Good cash flow from a lot of coonsumer products.
Bullish. International.No generic drug problems. Good cash flow from a lot of coonsumer products.
Bill MacLachlan
Director, Mawer Investment Mngmnt
Price
$61.370
Owned
Unknown
DON'T BUY
DON'T BUY
April 19, 2002
Great company, but expensive.
Great company, but expensive.
Brad Willock
Vice President and Senior Portfolio Manager, RBC Asset Management
Price
$64.490
Owned
Unknown
BUY
BUY
February 22, 2002
Prefers this and Pfizer over Merk.
Johnson & Johnson (JNJ-N)
February 22, 2002
Prefers this and Pfizer over Merk.
Brad Willock
Vice President and Senior Portfolio Manager, RBC Asset Management
Price
$58.720
Owned
Unknown
BUY
BUY
January 22, 2002
Some good products. Grows well.
Johnson & Johnson (JNJ-N)
January 22, 2002
Some good products. Grows well.
John Zechner
Chairman, J. Zechner & Assoc
Price
$59.120
Owned
Unknown
BUY
BUY
January 18, 2002
Not cheap. Good stability. Good product development skills.
Johnson & Johnson (JNJ-N)
January 18, 2002
Not cheap. Good stability. Good product development skills.
David Baskin
President, Baskin Wealth Management
Price
$59.700
Owned
Unknown
STRONG BUY
STRONG BUY
January 11, 2002
Steady earnings. Demographics on health needs are good.
Johnson & Johnson (JNJ-N)
January 11, 2002
Steady earnings. Demographics on health needs are good.
Steven Wippersteg
Senior Vice President and Portfolio Manager, Strategic Nova
Price
$58.230
Owned
Unknown
DON'T BUY
DON'T BUY
January 2, 2002
A bit expensive, but a good hold. Buy near $50.
A bit expensive, but a good hold. Buy near $50.
Brad Willock
Vice President and Senior Portfolio Manager, RBC Asset Management
Price
$58.700
Owned
Unknown
DON'T BUY
DON'T BUY
December 28, 2001
Had a nice run. Probably near its top.
Johnson & Johnson (JNJ-N)
December 28, 2001
Had a nice run. Probably near its top.
Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$59.860
Owned
Unknown
Showing 406 to 420 of 431 entries